Retatrutide is a next-generation triple agonist (GLP-1, GIP, and GCGR) widely examined in laboratory studies focused on energy balance, metabolic regulation, and multi-pathway peptide signalling
Diabetes Care, 46(Supplement_1), S1-S291.
Semaglutide is an appetite suppressant that is primarily used to treat type 2 diabetes and obesity, as indicated, and approved by the Food and Drug Administration (FDA)
Potential Increase in Fat Gain After Stopping Medication : If muscle mass is lost but fat mass remains, individuals may be more prone to weight regain once they discontinue GLP-1 medications
Food and Drug Administration GIP: Glucose-dependent Insulinotropic Polypeptide GLP-1 RAs: Glucagon-like peptide-1 receptor agonists GQ: Grazing Questionnaire HR: Hazard Ratio LABS: Longitudinal Assessment of Bariatric Surgery PHQ-9: Patient Health Questionnaire-9 RCTs: Randomized Controlled Trials Rep(eat)-Q: Repetitive Eating Questionnaire RR: Risk Ratio SGLT2: Sodium-Glucose Cotransporter-2 Inhibitors SMD: Standardized Mean Difference STEP: Semaglutide Treatment Effect in People with obesity TOS: The Obesity Society USPSTF: U.S
This includes a complete metabolic panel, fasting insulin, HbA1c, fasting glucose, lipid panel (complete with LDL particle count if available), IGF-1, growth hormone levels (random and stimulated if possible), liver enzymes (ALT, AST, GGT), kidney function markers (creatinine, BUN, eGFR), complete blood count, and thyroid panel
